| Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... New England Journal of Medicine 370 (3), 211-221, 2014 | 1565 | 2014 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1078 | 2019 |
| All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study DR Nelson, JN Cooper, JP Lalezari, E Lawitz, PJ Pockros, N Gitlin, ... Hepatology 61 (4), 1127-1135, 2015 | 895 | 2015 |
| Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study A Poonawala, SP Nair, PJ Thuluvath Hepatology 32 (4), 689-692, 2000 | 756 | 2000 |
| Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation S Nair, S Verma, PJ Thuluvath Hepatology 35 (5), 1179-1185, 2002 | 637 | 2002 |
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma AX Zhu, O Rosmorduc, TRJ Evans, PJ Ross, A Santoro, FJ Carrilho, ... Journal of Clinical Oncology 33 (6), 559-566, 2015 | 598 | 2015 |
| Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States S Nair, S Verma, PJ Thuluvath Hepatology 35 (1), 105-109, 2002 | 478 | 2002 |
| Liver transplantation in the United States, 1999–2008 PJ Thuluvath, MK Guidinger, JJ Fung, LB Johnson, SC Rayhill, ... American Journal of Transplantation 10 (4p2), 1003-1019, 2010 | 472 | 2010 |
| Acute hepatitis C A Maheshwari, S Ray, PJ Thuluvath The Lancet 372 (9635), 321-332, 2008 | 470 | 2008 |
| A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial F Wong, AT Blei, LM Blendis, PJ Thuluvath, ... Hepatology 37 (1), 182-191, 2003 | 360 | 2003 |
| MicroRNA‐21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3 FM Selaru, AV Olaru, T Kan, S David, Y Cheng, Y Mori, J Yang, B Paun, ... Hepatology 49 (5), 1595-1601, 2009 | 349 | 2009 |
| Independent risk factors and natural history of renal dysfunction in liver transplant recipients A Pawarode, DM Fine, PJ Thuluvath Liver transplantation 9 (7), 741-747, 2003 | 315 | 2003 |
| The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time HY Yoo, CH Patt, JF Geschwind, PJ Thuluvath Journal of clinical oncology 21 (23), 4329-4335, 2003 | 299 | 2003 |
| Development of a definition of postacute sequelae of SARS-CoV-2 infection T Thaweethai, SE Jolley, EW Karlson, EB Levitan, B Levy, GA McComsey, ... Jama 329 (22), 1934-1946, 2023 | 293 | 2023 |
| Biliary complications after liver transplantation: the role of endoscopy PJ Thuluvath, PR Pfau, MB Kimmey, GG Ginsberg Endoscopy 37 (09), 857-863, 2005 | 266 | 2005 |
| Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension N Chalasani, MF Abdelmalek, G Garcia-Tsao, R Vuppalanchi, N Alkhouri, ... Gastroenterology 158 (5), 1334-1345. e5, 2020 | 257 | 2020 |
| NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosis JG O'leary, KR Reddy, G Garcia‐Tsao, SW Biggins, F Wong, MB Fallon, ... Hepatology 67 (6), 2367-2374, 2018 | 244 | 2018 |
| An endoscopic approach to biliary complications following orthotopic liver transplantation PJ Thuluvath, T Atassi, J Lee Liver International 23 (3), 156-162, 2003 | 242 | 2003 |
| Spontaneous bacterial peritonitis—in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998 PJ Thuluvath, S Morss, R Thompson Official journal of the American College of Gastroenterology| ACG 96 (4 …, 2001 | 236 | 2001 |
| Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection GT Everson, KD Sims, M Rodriguez-Torres, C Hézode, E Lawitz, ... Gastroenterology 146 (2), 420-429, 2014 | 235 | 2014 |
